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A B S T R A C T
To identify molecular markers indicative of response to tamoxifen and easily implemented
in the routine setting, we recently reported three gene signatures that could stratify post-
menopausal tamoxifen-treated, estrogen receptor-positive (ERþ) patients according to
outcome in the adjuvant setting. Here, we evaluated the predictive potential of the total
of 14 genes included in the 3 gene signatures using 2 hormone-na€ıve Dutch ERþ cohorts
of a total of 285 recurrent breast cancer patients treated with first-line tamoxifen.
mRNA levels were measured by reverse transcriptase quantitative PCR (RT-qPCR) and the
length of progression-free survival (PFS) was used as the primary endpoint. A ManneWhit-
ney U test was used to select for differentially expressed genes between tumors of patients
who showed or did not show progressive disease within 6 months after start of tamoxifen
treatment. Cox univariate and multivariate regression analysis for PFS were used to further
assess their (independent) predictive potential.
Five (BCAR3, BCL2, ESR1, IGF1R, and NCOA1) of the 14 genes analyzed showed significantly
higher mRNA levels in tumors of patients who showed no disease progression within 6
months. Only BCAR3, BCL2 and NAT1 were significantly associated with a favorable PFS
in multivariate analysis that included the traditional predictive factors: age, dominant
Abbreviations: DCIS, ductal carcinoma in situ; EMC, Rotterdam Dutch cohort; ER, estrogen receptor; ERþ, estrogen receptor-positive;
ERBB2, HER2/ERBB2 mRNA level; ESR1, estrogen receptor alpha mRNA level; IDC, infiltrating ductal carcinoma; ILC, infiltrating lobular
carcinoma; LNN, lymph node-negative; M1, patients which developed distant metastasis within 1 month after primary surgery; M2, pa-
tients with SSCI; MFS, metastasis-free survival; PFS, progression-free survival; PGR, progesterone receptor mRNA level; PR, progesterone
receptor; RT-qPCR, reverse transcriptase quantitative PCR; RUMC, Nijmegen Dutch cohort; SCCI, supraclavicular-/cervical-/contralateral
axillary/parasternal-/lymph nodes positive.
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relapse site, disease-free interval, ER and progesterone receptor (PGR), and adjuvant
chemotherapy.
This study shows that BCAR3, BCL2 and NAT1 in particular exhibit predictive promise
regarding the efficacy of tamoxifen treatment in recurrent disease, in addition to the pre-
viously shown favorable outcome in the adjuvant setting.
ª 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights
reserved.
1. Introduction
Tamoxifen is an effective anti-estrogen treatment for patients
with estrogen receptor-positive (ERþ) breast cancer in both
adjuvant and recurrent disease. However, approximately
30% of such patients receiving adjuvant tamoxifen therapy
experience recurrence within 15 years, and most patients
with advanced disease will eventually develop tamoxifen
resistance, highlighting the need for markers to stratify these
patients for optimal treatment.
We recently published a promising set of gene signatures
that could stratify post-menopausal, tamoxifen-treated, ERþ
patients according to outcome in the adjuvant setting using
tumor tissues from 108 post-menopausal breast cancer pa-
tients. The gene expression of 59 literature-based candidate
genes was investigated using reverse-transcribed quantita-
tive-PCR (RT-qPCR), and the end-point was clinically verified
as recurrence to distant organs or to the ipsilateral breast
(Lyng et al., 2013). The data revealed three gene signatures
consisting of a total of 14 genes (AKT1, BCAR3, BCL2, CDKN1A,
CGA, EGFR, ESR1, IGF1R, NAT1, NCOA1, NRG1, PRKCD, PRKCE
and TFF1). The strongest prediction of outcome (75% accuracy)
was obtained with a 2-gene combination of BCL2 and CDKN1A
and confirmed by independent examination of 4 previously-
reported microarray datasets of tamoxifen-treated patient
samples in the adjuvant setting (n ¼ 503)(Chanrion et al.,
2008; Loi et al., 2008;Ma et al., 2004; Zhang et al., 2009). The pre-
dictive value was further validated by comparing the ability of
the genes to predict recurrence in an additional, previously-
published, cohort (Loi et al., 2007) consisting of both adjuvant
tamoxifen-treated and untreated patients (Lyng et al., 2013).
In an adjuvant setting such as the original study (Lyng
et al., 2013), a marker might predict a tumors response to
tamoxifen, but also inevitably addresses the tumors intrinsic
aggressiveness (Ma et al., 2004). This is not a significant issue
in the recurrent setting or in PFS analysis if a correction is
made for disease-free interval (time between surgery and
the occurrence of metastasis), thus favoring this clinical set-
up for the discovery or validation of predictive markers
regardless of their prognostic value.
In the current study, we investigated the performance of
the 14 genes in a new clinical setting (recurrent vs. previously
adjuvant) as well as in an independent laboratory, each using
different sample handling and technical protocols. This study
comprises a combined analysis of 285 endocrine treatment-
na€ıve ERþ breast cancer patients from two independent clin-
ical cohorts (Rotterdam [EMC; n ¼ 225] and Nijmegen [RUMC;
n ¼ 60]) in which hormone-na€ıve patients at the time of
clinically-detected metastasis received tamoxifen as first-
line therapy, and for whomdisease statuswasmonitored dur-
ing treatment. The main end-point for this study was defined
by the length of PFS.
2. Methods and materials
2.1. Patients
In this retrospective study, coded primary tumor tissues were
used in accordance with the Code of Conduct of the Federa-
tion of Medical Scientific Societies in the Netherlands (http://
www.federa.org/codes-conduct). In the years the tumors
were collected (1981e1996), tumor ER and PR levels were
routinely determined in cytosolic extracts by ligand binding
assay or enzyme immunoassay (Foekens et al., 1989). The
cut-off classifying primary breast tumors as ER- and/or PR-
positive was 10 fmol/mg cytosolic protein. The following in-
clusion and exclusion criteria were used: 1) Only female pa-
tients with measurable disease were evaluated; 2) all
patients had undergone primary treatment (surgery with or
without radiotherapy) for breast cancer; 3) only patients
with ER protein-positive primary tumorswho received tamox-
ifen as first-line therapy were included; 4) patients with resid-
ual disease diagnosed within 1 month after primary surgery
were excluded; 5) patients with non-invasive breast cancer
or those who received neo-adjuvant therapy or were exposed
to hormonal adjuvant treatment were excluded; 6) patients
with no response who were still alive or patients that stopped
therapy for reasons other than progression (e.g. subjective or
objective toxicity) were excluded if their follow-up period dur-
ing tamoxifen treatment was three months or less; 7) patients
who previously experienced another cancer (except basal cell
skin cancer or early-stage cervical cancer stage Ia/Ib) were
excluded; and 8) patients with over 100 mg frozen primary tu-
mor samples yielding good quality RNA from sections con-
taining at least 30% of the nuclei epithelial tumor cell origin
and distributed uniformly over at least 70% of the section
area were included.
2.2. Cohort description and clinical end point
The protocol to study biological markers associated with dis-
ease outcome was approved by the Medical Ethics Committee
of the Erasmus Medical Center Rotterdam, The Netherlands
(MEC 02.953). Of the 285 patients (n ¼ 225 from Rotterdam
(EMC) and n ¼ 60 from Nijmegen (RUMC), 32 presented with
distant metastasis at diagnosis or developed distant metas-
tasis (including supraclavicular lymph node metastasis)
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within 1 month after primary surgery (M1-patients). These 32
patients and the 253 patients who developed recurrence dur-
ing follow-up [25 patients with local-regional relapse (LRR),
228 with distant metastasis] received tamoxifen as first-line
therapy. All patients were ERþ and endocrine therapy-naive,
while 38 received adjuvant chemotherapy. The median time
between primary surgery and initiation of therapy was 24
months (range, 0e120 months). The median follow-up of pa-
tients alive after primary surgery was 95 months (range,
9e240 months), and 45 months (range, 3e178 months) after
start of first-line tamoxifen therapy. For 182 patients (64%),
disease progression was controlled by tamoxifen for at least
6 months after initiation of therapy. At the end of the
follow-up period, 268 (94%) patients had developed tumor pro-
gression and 222 (78%) had died. Relevant additional details on
patient and tumor characteristics are summarized in Table 1.
Details of the Rotterdam (EMC) and the Nijmegen (RUMC)
Dutch cohorts are available online (Supplemental File 1). Post-
operative follow-up involved standard routine examinations
as previously described (Martens et al., 2005; Meijer-van
Gelder et al., 2004). The date of diagnosis of recurrence was
defined as that at confirmation of metastasis after symptoms
reported by the patient or after detection of clinical signs at
regular follow-up. To evaluate PFS, the start of first-line
tamoxifen therapy was set at zero and the end point at the
time of progression or the last date of follow-up.
2.3. RNA Extraction, cDNA synthesis and quantification
by RT-qPCR
Tissues from Nijmegen RUMC were transferred on dry ice to
the Rotterdam EMC laboratory for processing. Detailed proce-
dures for tissue processing, RNA extraction, cDNA synthesis
and quantification of mRNA transcripts by RT-qPCR have
been described (Sieuwerts et al., 2005). In brief, only tumor tis-
sues containing at least 30% invasive tumor cell nuclei were
processed with RNA Bee (Tel Test, Thermo Fisher Scientific
Inc.). After cDNA synthesis with the RevertAid H Minus First
Strand cDNA Synthesis Kit from Thermo Fisher Scientific
Inc, followed by an RNAse H step (Ambion, Life Technologies)
to degrade the remaining RNA, qPCR reactions were per-
formed using a Mx3000PTM Real-Time PCR System (Agilent,
Amsterdam, The Netherlands). PCR reactions were done in a
final volume of 25 mL containing cDNA synthesized from 5 to
15 ng of total RNA. SYBR-based assays were performed with
330 nM forward and reverse primer and 12.5 mL Absolute
QPCR SYBR Green mastermix containing ROX (Abgene
Limited, Epsom, UK). After 15 min of denaturation and activa-
tion of the Taq-DNA polymerase, PCR productswere amplified
in 35 cycles with 15 s of denaturing at 95 C, 30 s of annealing
at 62 C, followed by data acquisition at 72 C and 79 C. For the
Taqman Gene Expression assays fromApplied BioSystems, all
performed with Absolute QPCR Universal mastermix con-
taining ROX fromAbgene, PCR settings were as recommended
by the manufacturer. Validations to ensure PCR specificity
were done as described (Sieuwerts et al., 2005). In brief,
when amplification rounds for a specific target exceeded 35
cycles for the SYBR-based assays and 40 cycles for the Taq-
man Gene Expression assays, quantities were considered to
be undetectable and were arbitrarily set at 50% of the lowest
expression level measurable at the quantification detection
threshold (Cq ¼ 0.01). In addition to a negative genomic DNA
control sample, a standard curve of a serially-diluted cDNA
breast tumor pool sample was included in each PCR plate to
control PCR efficiency and harmonize the data between plates.
Concentrations of target genes, expressed relative to the
Dutch reference gene set consisting of hydroxymethylbilane
synthase (HMBS ), hypoxanthine phosphoribosyltransferase
1 (HPRT1) and TATA-box binding protein (TBP), were quanti-
fied as follows: dCq mRNA target ¼ 2Cq reference gene setCq target
gene. To analyze the predictive value of gene combinations, we
first centered dCq levels on zero and then added the dCq
values of the individual genes in the gene combinations
divided by the final number of genes in the combination. All
primer sequences and Taqman Gene Expression assays are
listed in Supplemental File 2.
2.4. Statistics
For statistical computations, STATA statistical package 12
(STATACorp, College Station, TX) and SPSS (IBM) version 20
were used. Differences in levels were assessed with the Man-
neWhitney U test and between categorized variables with the
Fisher Exact Probability Test, both using patient and tumor
characteristics as grouping variables. The strength of associa-
tions between continuous variables was tested with the
Spearman rank correlation (rs). The Cox proportional hazard
model was used to calculate the hazard ratio (HR) and 95%
confidence interval (CI) in the analyses of PFS, the latter
defined as the time elapsed between the start of tamoxifen
treatment for recurrent disease and the first detection of pro-
gressive disease. Visual inspection of the log minus log Cox
regression plots was used to check the proportional hazards
assumption. The ShapiroeWilk test was used to test for
normal distribution after log transformation. All P-values are
two-sided and P< 0.05was considered statistically significant.
3. Results
3.1. Reproducibility measuring the 14 genes in the
independent Dutch laboratory
The RT-qPCR reproducibility of the 14 genes comprising the 3
gene signature sets identified in the original study (Figure 1A)
(Lyng et al., 2013) was investigated by transferring RNA of 10
patients stored since the original study approximately 6 years
ago to the Dutch reference laboratory (EMC). At the original
Danish site, cDNA synthesis, qPCR and settings were conduct-
ed as previously described (Lyng et al., 2013). In brief, qPCR
was conducted in 96-well plates containing a total volume of
25 mL (vs. 384-well previously with 2 mL volume reactions). In
the present study, cDNA synthesis, qPCR and settings were
performed according to EMC’s standard operation procedures
(Sieuwerts et al., 2005) for kits, gene expression assays and
reference gene set to normalize the data. As only 10 RNA sam-
ples were compared, a test for normality could not be con-
ducted and non-parametric Spearman Rank correlation tests
were therefore performed to compare gene expression levels
in these 10 RNA samples as measured in both laboratories.
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Table 1 e Clinical and biological factors of the patients and tumors used in the study.
Clinical and biological
factors
No. of
patientsa
PFS  6
months
PFS > 6 months P
All patients
PFS  6 months 102 102 0
PFS > 6 months 182 0 182
Age at primary surgery
50 years 79 31 48 0.37b
>50 years 205 71 134
Age at start 1st line Tamoxifen
50 years 59 25 34 0.16b
>50 years 225 77 148
Menopausal status at primary surgery
Pre-menopausal 65 29 36 0.07c
Post-menopausal 199 64 135
Peri-menopausal 11 6 5
Chirurgy primary tumor
Ablatio 177 59 118 0.25c
Lumpectomy 107 43 64
Axillary dissection
No 19 9 10 0.32c
Yes 265 93 172
Tumor grade
Good/moderate 51 15 36 0.24c
Poor 148 58 90
Tumor size primary tumor
2 cm 83 34 49 0.17b
>2e5 cm 159 52 107
>5 cm þ pT4 36 14 22
Unknown 6 2 4
Histology primary tumor
IDC 177 64 113 0.53c
ILC 27 8 19
IDC þ ILC 5 1 4
Nodal status primary tumor
N0, no positive lymph nodes 131 42 89 0.31c
N1 þ N2, positive lymph
nodes
136 52 84
M-stage primary tumor
M0, no distant metastases
present
252 88 164 0.69c
M1, distant metastases
present
30 12 18
M2, SCCI 2 2 0
ESR1 primary tumor
Median 6.03 5.00 6.55 0.002b
Interquartile range 8.54 7.72 9.98
PGR primary tumor
Median 0.75 0.48 1.17 0.006b
Interquartile range 2.78 1.96 3.57
ERBB2 primary tumor
Median 3.79 3.54 3.87 0.82b
Interquartile range 5.19 5.37 5.20
Adjuvant systemic therapy
None 246 91 155 0.37c
Chemotherapy 38 11 27
Endocrine therapy 0 0 0
Adjuvant radio therapy
No 96 24 72 0.02c
Yes 161 64 97
Disease-free interval
1 yr 78 42 36 <0.001b
1e3 yr 113 38 75
>3 yr 93 22 71
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Despite the different settings, data correlated well (dCq
Danish ¼ 0.91  dCq Dutch  1.2, R2 ¼ 0.64, n ¼ 140,
P < 0.0001, Figure 1B) and the RT-qPCR assays were efficient
(median 100%, range 94%e102%, Supplemental File 2). Spe-
cifics of the gene expression assays used in both laboratories
and the resulting Spearman rank correlation coefficients and
P-values are given in Supplemental File 2.
3.2. Predictive value of the genes identified in the
adjuvant setting translated to the recurrent setting
Similar to the original study in the adjuvant setting (Lyng
et al., 2013), we first used single gene analysis to identify
the genes most significantly (P < 0.05) associated with PFS
in the recurrent setting. According the ShapiroeWilk test,
only the primary tumor levels of BCAR3, BCL2, NCOA1 and
PRKCD showed normal distributions after log transformation.
Therefore, we continued to use non-parametric analyses,
which showed that 5 of the 14 genes were significantly differ-
entially expressed in tumors of patients with a short PFS (6
months) compared with those with a longer PFS (>6 months)
(Table 2).
Note that 4 of the remaining 9 non-informative genes
(AKT1, CGA, NAT1 and TFF1) were also not identified as being
significantly associated with clinical outcome at the single
gene level in the original study on adjuvant tamoxifen. These
genes were part of the 2-, 8- and 9-gene prognostic tamoxifen
signatures identified by various statistical analyses (Lyng
et al., 2013). Only the 8-gene signature, which harbors 4 of
the 5 genes shown to be significant at the single gene level
in the recurrent setting, was also significant in the recurrent
setting (P ¼ 0.0074), but this 8-gene signature did not
Figure 1 e Reproducibility measuring the 14 genes in 10 RNA samples in the Danish and Dutch laboratories. A: Origin of the 14 gene transcripts
studied. The 2-, 8- and 9-gene signatures were previously identified by various statistical analyses for the adjuvant setting (Lyng et al., 2013). B:
Data of all 14 genes, measured in both the Dutch and Danish laboratories in 10 different clinical RNA samples. For both, data after normalization
with the in-house reference gene sets (dCq) are plotted. Note that only the values for TFF1 (brown dots) show a large range of values with high
concordance between the laboratories, but with a relatively higher expression if measured with the Dutch gene expression assay.
Table 1 e (continued )
Clinical and biological
factors
No. of
patientsa
PFS  6
months
PFS > 6 months P
Dominant site of relapse
Soft 26 7 19 0.46c
Bone 152 59 93
Viscera 106 36 70
Because of others and unknowns, numbers do not always add up to 284.
Abbreviations: EMC, Rotterdam Dutch cohort; RUMC, Nijmegen Dutch cohort; PFS, progression-free survival; ESR1, estrogen receptor alpha
mRNA level; PGR, progesterone receptor mRNA level; ERBB2, HER2/ERBB2mRNA level; IDC, infiltrating ductal carcinoma; ILC, infiltrating lobular
carcinoma; DCIS, ductal carcinoma in situ; SCCI, supraclavicular -/cervical -/contralateral axillary/parasternal-/lymph nodes positive.
a One patient, whowas followed for only 3months after start of first-line tamoxifen treatment and showed no signs of recurrent disease during
this time-frame, was excluded for this analysis.
b P for ManneWhitney U test (2-tailed).
c P Fisher Exact Probability Test (2-tailed).
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outperform BCL2 (P ¼ 0.0009) as a single marker (Table 2). For
the significant genes shown in Table 2, we divided the levels
in 2 and 4 equal parts and, in an exploratory analysis, we
calculated the positive and negative predictive values for the
various quarter combinations. The results summarized in
Table 3 show that high levels of the genes were more likely
to predict a favorable clinical outcome.
Next, after stratification for study cohort, we performed
Cox univariate and multivariate regression analyses for PFS
as a function of the mRNA levels of the significant genes.
High mRNA levels of ESR1, BCAR3, IGF1R and BCL2, but not
NCOA1, were significantly associated with a favorable PFS
(Table 4). Of the genes not identified as significantly associ-
ated with progression of disease within 6 months after start
of therapy (Table 2), only mRNA levels of NAT1 were in addi-
tion significantly associated with PFS in this analysis (Table
4). Moreover, in Cox multivariate regression analysis, high
BCL2 and NAT1 mRNA levels, when added separately to a
base model that included the traditional predictive factors
and adjuvant chemotherapy, were significantly associated
with a favorable PFS (Table 4). BCL2 was also significant
when analyzed as a continuous variable in both Cox univar-
iate (HR ¼ 0.75, 95% CI: 0.66e0.86, P < 0.0001) and multivariate
(HR ¼ 0.80, 95% CI: 0.69e0.93, P ¼ 0.0033) regression analyses.
The association of BCL2 (the 25% highest levels, Q4, versus
Q1-Q3) and NAT1 (the 75% highest levels, Q1-Q3, versus Q4)
with PFS is visualized in KaplaneMeier curves (Figure 2). In
addition to ESR1, which was already included in the base
model, BCAR3 significantly added to the multivariate model,
which is not surprising since most of the EMC samples
analyzed in the present study were also used in our original
study describing the predictive value of BCAR3 (van
Agthoven et al., 2009a). In Table 4, only the dichotomized
data resulting in the most significant associations of the
different genes with PFS are shown. Data for all dichotomized
cut-off values based on the distribution of the mRNA values
in quarters, including the genes not significantly differen-
tially expressed in tumors of patients with a short PFS (6
months) compared with those with a longer PFS (>6 months),
are shown in Supplemental File 3A.
Finally, data for post-menopausal patients only (n ¼ 200)
are shown in Supplemental File 3B, as this was the cohort
Table 2 e Predictive value of the 14 genes in the recurrent setting.
Gene P-value*/** Higher expressed in
BCL2 9.4E-04 PFS > 6 months
ESR1 3.3E-03 PFS > 6 months
IGF1R 8.8E-03 PFS > 6 months
BCAR3 2.3E-02 PFS > 6 months
NCOA1 4.9E-02 PFS > 6 months
EGFR 3.1E-01
NRG1 3.2E-01
TFF1 3.5E-01
PRKCE 3.7E-01
PRKCD 3.8E-01
CDNK1A 4.8E-01
AKT1 7.1E-01
NAT1 7.2E-01
CGA 9.3E-01
2-gene 1.1E-01
8-gene 7.4E-03 PFS > 6 months
9-gene 1.3E-01
One hundred and two 102 patients showed progression of disease
within 6 months after start of therapy, 182 patients showed no dis-
ease progression in this time frame. One patient, whowas followed
for only 3 months after start of tamoxifen treatment and showed
no signs of recurrent disease during this time-frame, was excluded
for this analysis .
*Grouping Variable: PFS > 6 months vs  6 months.
**KruskaleWallis test.
Table 3 e Performance of the identified genes in the recurrent setting to predict outcome on tamoxifen therapy.
Gene Groups tested PFS > 6 months PPV NPV
Specificity Sensitivity
BCL2 Q4 high vs Q1-Q3 low 88.2% 32.4% 83.1% 42.3%
Q3/4 high vs Q1/2 low 60.8% 55.5% 71.6% 43.4%
Q2-Q4 high vs Q1 low 31.4% 76.9% 66.7% 43.2%
ESR1 Q4 high vs Q1-Q3 low 81.4% 28.6% 73.2% 39.0%
Q3/4 high vs Q1/2 low 54.9% 52.7% 67.6% 39.4%
Q2-Q4 high vs Q1 low 37.3% 80.8% 69.7% 52.1%
IGF1R Q4 high vs Q1-Q3 low 82.4% 29.1% 74.6% 39.4%
Q3/4 high vs Q1/2 low 57.8% 53.8% 69.5% 41.3%
Q2-Q4 high vs Q1 low 32.4% 78.0% 67.3% 45.2%
BCAR3 Q4 high vs Q1-Q3 low 82.4% 29.1% 74.6% 39.4%
Q3/4 high vs Q1/2 low 55.9% 53.3% 68.3% 40.1%
Q2-Q4 high vs Q1 low 31.4% 78.0% 67.0% 44.4%
NCOA1 Q4 high vs Q1-Q3 low 81.4% 27.5% 72.5% 38.6%
Q3/4 high vs Q1/2 low 57.8% 53.3% 69.3% 41.0%
Q2-Q4 high vs Q1 low 32.4% 78.6% 67.5% 45.8%
%PPV; percentage of patients with a positive test who had not progressed within 6 months.
%NPV: percentage of patients with a negative test who did progress within 6 months.
PFS; progression-free survival.
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studied in the adjuvant setting in the original study (Lyng
et al., 2013). Restricting the analyses to post-menopausal
patients did only significantly alter the predictive outcome
of our univariate findings as presented in Table 4 for 2
markers. For the sub cohort containing only post-
menopausal patients, also CGA and TFF1 were significant
in both the univariate (Supplemental File 3B) and the multi-
variate setting (HR Q4 versus Q1-Q3 for CGA; 1.49, 95% CI:
1.04e2.13, P ¼ 0.031 and for TFF1: 0.69, 95% CI: 0.48e0.98,
P ¼ 0.037).
4. Discussion
In this study, we evaluated whether 14 genes previously iden-
tified in an adjuvant setting to be predictive of outcome with
tamoxifen therapy could also be of clinical relevance in the
advanced setting. In the adjuvant setting, in which the signa-
tures were constructed, patients who did not receive tamox-
ifen were included as a control group (Lyng et al., 2013). In
the advanced setting, however, patients cannot be withheld
Table 4 e Cox univariate and multivariate analysis for PFS in the recurrent setting.
Factor No. of patient Univariate analysisa Multivariate analysisa
HR 95% CI P HR 95% CI P
Base model
Age at start 1st line Tamoxifen
50 years 59 1 1
50e70 years 150 0.94 0.69 1.28 0.98 0.70 1.39
>70 years 76 0.85 0.60 1.22 6.7E-01 0.94 0.63 1.40 9.5E-01
Disease-free interval
1 yr 78 1 1
1e3 yr 113 0.71 0.52 0.96 0.65 0.47 0.89
>3 yr 94 0.54 0.40 0.75 1.0E-03 0.50 0.36 0.69 1.6E-04
Dominant site of relapse
Soft 27 1 1
Bone 152 1.63 1.02 2.62 1.66 1.03 2.69
Viscera 106 1.54 0.95 2.50 9.7E-02 1.78 1.08 2.92 7.2E-02
ESR1 primary tumor
Q1/2 low 143 1 1
Q3/4 high 142 0.78 0.61 1.00 4.9E-02 0.76 0.58 0.98 3.6E-02
PGR primary tumor
Q1/2 low 142 1 1
Q3/4 high 143 0.73 0.57 0.93 1.0E-02 0.72 0.57 0.93 1.0E-02
Adjuvant chemotherapy
No 247 1 1
Yes 38 0.98 0.68 1.40 9.1E-01 1.02 0.69 1.52 9.1E-01
Additions to the base modelb
BCL2 primary tumor
Q1eQ3 low 214 1 1
Q4 high 71 0.60 0.44 0.82 1.3E-03 0.67 0.49 0.93 1.7E-02
BCAR3 primary tumor
Q1eQ3 low 214 1 1
Q4 high 71 0.66 0.50 0.88 4.5E-03 0.69 0.51 0.92 1.1E-02
NAT1 primary tumor
Q1 low 73 1 1
Q1eQ3 high 212 0.68 0.51 0.89 5.8E-03 0.70 0.52 0.94 1.9E-02
IGF1R primary tumor
Q1 low 73 1 1
Q1-Q3 high 212 0.68 0.51 0.91 8.1E-03 0.77 0.57 1.06 1.1E-01
NCOA1 primary tumor
Q1eQ3 low 214 1
Q4 high 71 0.79 0.59 1.06 1.2E-01
Combined
1
BCL2 Q4 high 71 0.70 0.50 0.97 3.0E-02
BCAR3 Q4 high 71 0.73 0.55 0.99 3.9E-02
NAT1 Q1eQ3 high 212 0.70 0.52 0.95 2.0E-02
3 genes combined 20 0.45 0.26 0.78 4.0E-03
a Stratified for study cohort.
b Factors were separately introduced to the base multivariate model that included the following factors: age, disease-free interval, dominant
site of relapse, adjuvant chemotherapy and ER and PGR mRNA levels.
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therapy and a control group can never be included. All the pa-
tients we studied were adjuvant hormonal therapy na€ıve and
already had experienced a distant metastasis. Thus, all these
patients were per definition poor prognosis cases and as
such not a cohort suitable to study prognostic markers able
to differentiate between good and poor prognosis patients.
Furthermore, to correct for potential prognostic associations
of markers, we also corrected for the length of disease-free in-
terval. We should realize that the molecular characteristics of
the primary tumor may differ from those of the metastases
and that ideally the metastatic tumors that need treatment
should have been analyzed. However, obtaining biopsies
from (all) available metastases is a cumbersome and painful
procedure for the patients, and frequently not possible.
Currently, in clinical practice the characteristics of the pri-
mary tumor (ER, PR and HER2 status) are used to guide treat-
ment decisions in metastatic disease, although this is slowly
changing as clinicians realize that better treatment decisions
can be obtained by analyzing the metastasis themselves.
Possibly in the future the molecular characterization of circu-
lating tumor cells or cell-free DNA will be feasible, such that
treatment decisions of metastatic patients can be based on
the molecular characteristics and molecular heterogeneity of
the various metastases.
Current prognostic and predictivemarker profiles for endo-
crine treatment of ER-positive breast cancer seem to differ as
to greater or lesser efficacy in high or low risk patients as well
as to whether the marker profile predicts outcome over the
short (1e5 year) or long term (over 5 years) (Dowsett et al.,
2013; Sestak et al., 2013; Sgroi et al., 2013). Since certain genes
may be useful only in a subpopulation of tamoxifen-treated
ER-positive breast cancer patients, it was not surprising that
not all genes identified as useful in the adjuvant setting
were also informative in the recurrent setting. This was also
demonstrated by our finding that low levels of CGA and high
levels of TFF1 were only significantly associated with favor-
able PFS in this advanced setting when analyzed in the sub
cohort of post-menopausal patients only. Importantly, we
found BCL2 and NAT1 to be predictive in a multivariate recur-
rent setting, together with ESR1 and BCAR3, which have previ-
ously been shown to be associated with a favorable outcome
in tamoxifen therapy in the recurrent setting (van Agthoven
et al., 2009a). Note that high levels of these genes were all
more likely to correctly predict favorable versus unfavorable
outcomes (Table 3). This might render these genes less clini-
cally relevant when seeking markers predictive of poor
response in patients who might benefit from other therapies.
Nevertheless, stratification options to specifically select pa-
tients who are likely to respond favorably to tamoxifen may
protect these patients from overtreatment. This is especially
true in view of a recent meta-analysis study showing that
extended adjuvant tamoxifen is not associated with signifi-
cantly reduced recurrence in unselected patients (Al-
Mubarak et al., 2014), demonstrating the need for better
stratification.
To investigate whether the lack of association with PFS in
the recurrent setting for the other genes was not simply due
to an association of the genes with intrinsic aggressive
behavior in the adjuvant setting, we also analyzed the pure
prognostic value of our candidate genes. Affymetrix U133
microarray data of the single genes showed that 2 of the 13
genes present on the platform (BCAR3 and BCL2) were also
significantly (P < 0.05) associated with shorter metastasis-
free survival (MFS) in our previously published untreated
lymph node-negative (LNN) ERþ cohort (Smid et al., 2008).
No correlation with MFS was found for the other genes
Figure 2 e KaplaneMeier curve for PFS as a function of BCL2 and NAT1 mRNA levels. Progression-free survival (PFS) of 285 ERepositive
breast cancer patients with recurrent disease treated with first-line tamoxifen monotherapy. A: High BCL2, the 25% highest mRNA values; low
BCL2, the 75% lowest mRNA values. B: High NAT1, the 75% highest mRNA values; low NAT1, the 25% lowest mRNA values. Patients at risk at
12-month intervals and LogRank P-values are indicated.
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(Supplemental File 4), indicating that the lack of association
with PFS in the recurrent setting for the other genes was not
due to association with intrinsic aggressive behavior in the
adjuvant setting. Indeed, all genes evaluated were selected
based on the literature and their relation with tamoxifen
treatment outcome. Genes uniformly identified to be associ-
ated with prognosis and solely with the ERþ phenotype were
excluded to ensure a focus on genes that might prove to be
purely predictive (Lyng et al., 2013). BCAR3, BCL2, ESR1 and
NAT1 are therefore well-documented in the field of prognostic
and predictive markers.
Several studies have implicated high levels of the anti-
apoptotic oncogene BCL2 as a marker for active ER-signaling,
thus more likely to respond to anti-estrogen therapies
(Henriksen et al., 2009; Larsen et al., 2012). BCL2 is one of the
21 gene Oncotype DX RT-qPCR assay used to predict which pa-
tients with LNN ERþ disease would benefit from adjuvant
tamoxifen and/or chemotherapy (Albain et al., 2010; Paik,
2007; Paik et al., 2006). BCL2 is also part of the PAM50 gene
set, a microarray-based risk predictor for breast cancer based
on intrinsic subtypes (Parker et al., 2009). A large analysis of
data from 7230 primary breast cancers showed that BCL2 as
a single marker had a strong influence on the established
prognostic models, including the St. Gallen, the Nottingham
Prognostic Index and the TNMmodels. Favorable clinicopath-
ologic features and a strong correlation with ER and PR were
suggested as the causes of superior survival in patients with
BCL2-positive breast cancer (Hwang et al., 2012). More specif-
ically, Vaillant and colleagues demonstrated recently that tar-
geting BCL2 with the BH3 mimetics ABT-737 improves the
response of xenografts from primary ERþ breast tumors to
endocrine therapy and reduces tamoxifen-induced endome-
trial hyperplasia, a strategy with potential clinical applica-
bility utilizing BCL2 as a companion marker (Vaillant et al.,
2013).
NAT1 was one of the 3 genes in the optimal 3-gene combi-
nation that consisted of BCL2-CDKN1A-NAT1 in the adjuvant
setting (Lyng et al., 2013). In addition, low levels of this gene
have been indicated before in relation to tamoxifen resistance
in the adjuvant setting and suggested NAT1 as a new ER-
responsive gene for breast cancer (Bieche et al., 2004; Kim
et al., 2010). NAT1 (N-acetyltransferase 1) encodes for a phase
II drug-metabolizing enzyme, which plays a role in the meta-
bolism of tamoxifen (Bieche et al., 2004). It’s mode of action
therefore differs from that of BCL2. NAT1 is often methylated,
resulting in a down-regulated expression (as also observed in
our studies), in tamoxifen-resistant tumors compared to con-
trol cancers (Kim et al., 2010).
BCAR3 (breast cancer anti-estrogen resistance gene 3) was
identified in a search for genes involved in the development
of estrogen resistance (van Agthoven et al., 1998; van
Agthoven et al., 2009b). However, and in contrast to the func-
tion of BCL2, estrogen independence mediated by BCAR3 is
transmitted through mechanisms distinct from the ER-
signaling pathway (Dorssers et al., 2005). BCAR3, as part of
an intracellular signal transduction pathway that causes
estrogen-independent proliferation in human breast cancer
cells, promotes cell motility and adhesion, processes required
for cells to become metastatic (Oh et al., 2013; Wilson et al.,
2013). Additional studies from our group demonstrated that
high levels of BCAR3 were associated with clinical benefit
and prolonged PFS (van Agthoven et al., 2009a), which has
now been validated in a larger cohort for both the adjuvant
(Danish cohort) and the recurrent settings (Dutch cohorts,
which also include the original cohort used to identify
BCAR3 as a predictive marker). Of note, high levels of BCAR3,
BCL2 and NAT1 were also significantly associated with favor-
able PFS (P ¼ 0.039, P ¼ 0.030 and P ¼ 0.020, respectively)
when combined in the Cox multivariate regression analysis
(Table 4), indicating their modes of action with respect to
outcome on tamoxifen are indeed at least partly independent.
In summary, this study shows that BCL2, BCAR3 and NAT1,
three genes with different modes of action, exhibit potential
to predict favorable outcome of tamoxifen therapy in both
the adjuvant and recurrent settings. The predictive power of
the genes persisted despite different clinical settings (adju-
vant vs. first-line treatment, menopausal status, and adjuvant
chemotherapy), clinical sampling (countries, laboratories) and
molecular assays (cDNA synthesis protocol, qPCR assays, and
normalization procedures). This study provides support for
the findings of several other studies (Albain et al., 2009;
Hwang et al., 2012; Kerr and Wittliff, 2011; Kolacinska et al.,
2012; Linke et al., 2006; Lyng et al., 2013; Mangerini et al.,
2012; Nehra et al., 2010; Paik, 2007; Sgroi et al., 2013; Tozlu
et al., 2006; Wang et al., 2009) indicating that BCL2 is a
biomarker for endocrine response. The addition of BCL2 (and
NAT1 and BCAR3) to standard biological measures might be
considered for future hormone receptor-positive clinical
studies.
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